Vita Life Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Vita Life Sciences yıllık ortalama 19.8% oranında kazançlarını artırırken, Pharmaceuticals sektöründe kazançlar growing at 35.4% annual. Gelirler growing yılda ortalama 14.1% oranında artmaktadır. Vita Life Sciences'in özkaynak karlılığı 19.3% ve net marjı 11.9%'dir.

Anahtar bilgiler

19.8%

Kazanç büyüme oranı

19.7%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi	31.2%
Gelir büyüme oranı	14.1%
Özkaynak getirisi	19.3%
Net Marj	11.9%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Gelir ve Gider Dağılımı

Vita Life Sciences nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

CHIA:VLS Gelir, gider ve kazançlar (AUD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	79	9	34
31 Mar 24	77	9	32
31 Dec 23	74	9	31
30 Sep 23	71	8	30
30 Jun 23	69	7	29
31 Mar 23	68	7	29
31 Dec 22	67	7	29
30 Sep 22	65	8	27
30 Jun 22	64	8	26
31 Mar 22	61	8	25
31 Dec 21	57	8	24
30 Sep 21	54	8	23
30 Jun 21	50	7	22
31 Mar 21	48	6	22
31 Dec 20	46	6	21
30 Sep 20	46	6	22
30 Jun 20	45	5	22
31 Mar 20	44	4	23
31 Dec 19	42	3	23
30 Sep 19	42	2	23
30 Jun 19	41	2	23
31 Mar 19	41	2	22
31 Dec 18	41	2	21
30 Sep 18	40	3	21
30 Jun 18	40	4	21
31 Mar 18	38	3	20
31 Dec 17	37	3	20
30 Sep 17	37	3	20
30 Jun 17	37	3	20
31 Mar 17	38	3	20
31 Dec 16	38	3	20
30 Sep 16	38	4	20
30 Jun 16	38	5	20
31 Mar 16	39	5	21
31 Dec 15	39	4	21
30 Sep 15	38	4	20
30 Jun 15	37	4	20
31 Mar 15	37	6	20
31 Dec 14	37	7	19
30 Sep 14	36	7	19
30 Jun 14	36	7	19
31 Mar 14	36	6	19
31 Dec 13	35	5	18

Kaliteli Kazançlar: VLS yüksek kaliteli kazançlar sağlıyor.

Büyüyen Kar Marjı: VLS 'nin mevcut net kar marjları (11.9%) geçen yılın (10.8%) sinden daha yüksektir.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: VLS şirketinin kazancı son 5 yılda yılda 19.8% oranında arttı.

Büyüme Hızlandırma: VLS 'un son bir yıldaki kazanç büyümesi ( 26.6% ) 5 yıllık ortalamasını (yıllık 19.8% ) aşıyor.

Kazançlar vs. Sektör: VLS geçen yılki kazanç büyümesi ( 26.6% ) Pharmaceuticals sektörünün 46.5% performansını geride bırakmadı.

Özkaynak Getirisi

Yüksek ROE: VLS 'nin Özsermaye Getirisi ( 19.3% ) düşük olarak değerlendiriliyor.

Vita Life Sciences Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 4/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Recent updates

Non-Executive Chairman recently sold AU$654k worth of stock

New minor risk - Insider selling

MD & Director recently sold AU$1.9m worth of stock

Upcoming dividend of AU$0.06 per share

Vita Life Sciences Limited, Annual General Meeting, May 15, 2024

Final dividend increased to AU$0.06

Full year 2023 earnings released: EPS: AU$0.17 (vs AU$0.13 in FY 2022)

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Full Year Ending December 31, 2023

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share at 3.7% yield

Less than half of directors are independent

Vita Life Sciences Limited Announces Interim Dividend for the Six Months Ended June 30, 2023, 6 October 2023

Vita Life Sciences Limited Appoints Peter Osborne as an Independent Non-Executive Director

No independent directors

No independent directors

No independent directors

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

Upcoming dividend of AU$0.033 per share at 3.9% yield

No independent directors

Full year 2022 earnings released: EPS: AU$0.13 (vs AU$0.16 in FY 2021)

No independent directors

No independent directors

No independent directors

No independent directors

Vita Life Sciences Provides Earnings Guidance for the Full Year Ending 31 December 2022

No independent directors

Less than half of directors are independent

Vita Life Sciences Limited Announces Board Changes, Effective 30 September 2022

Upcoming dividend of AU$0.028 per share

Vita Life Sciences Limited Declares Fully Franked Interim Dividend for the Six Months Ended June 30, 2022, Payable on 7 October 2022

First half 2022 earnings released: EPS: AU$0.069 (vs AU$0.07 in 1H 2021)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2022

Less than half of directors are independent

Upcoming dividend of AU$0.03 per share

Investor sentiment improved over the past week

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Vita Life Sciences Limited Announces Dividend for Six Months Ended December 31, 2021, Payable on April 7, 2022

Less than half of directors are independent

Less than half of directors are independent

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Upcoming dividend of AU$0.028 per share

First half 2021 earnings released: EPS AU$0.07 (vs AU$0.058 in 1H 2020)

Less than half of directors are independent

Less than half of directors are independent

Vita Life Sciences Limited Provides Earnings Guidance for the Half Year Ending June 30, 2021

Upcoming Dividend of AU$0.015 Per Share

Earnings released

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin